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Receptor-interacting protein kinase-3 (RIP3 or RIPK3) is an essential part of the cellular machinery that executes 
“programmed” or “regulated” necrosis. Here we show that programmed necrosis is activated in response to many 
chemotherapeutic agents and contributes to chemotherapy-induced cell death. However, we show that RIP3 expres-
sion is often silenced in cancer cells due to genomic methylation near its transcriptional start site, thus RIP3-depen-
dent activation of MLKL and downstream programmed necrosis during chemotherapeutic death is largely repressed. 
Nevertheless, treatment with hypomethylating agents restores RIP3 expression, and thereby promotes sensitivity to 
chemotherapeutics in a RIP3-dependent manner. RIP3 expression is reduced in tumors compared to normal tissue 
in 85% of breast cancer patients, suggesting that RIP3 deficiency is positively selected during tumor growth/develop-
ment. Since hypomethylating agents are reasonably well-tolerated in patients, we propose that RIP3-deficient cancer 
patients may benefit from receiving hypomethylating agents to induce RIP3 expression prior to treatment with con-
ventional chemotherapeutics. 
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Introduction
Resistance to cell death is one hallmark of cancer 
cells, and tumor cells have developed a variety of strat-
egies to evade cell death [1]. Approaches that overcome 
such resistance to cell death would therefore be benefi-
cial in cancer therapy and treatment, and allow previous-
ly developed chemotherapeutic drugs to be used more ef-
fectively. Many previously used stratagems have focused 
on restoring the ability of a cell to undergo apoptosis. 
However, other forms of cell death also exist. 
The “programmed” or “regulated” necrotic cell death 
pathway is activated in response to death receptor ligands 
and other types of cellular stress [2, 3]. Programmed 
necrotic cell death is distinguished from its counterpart, 
apoptosis, in that caspase activation is dispensable for 
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cell death, and, unlike apoptosis, programmed necrosis 
results in plasma membrane rupture, thus spilling the 
contents of the cell and triggering the immune system 
and inflammation [3, 4]. 
The acceptance of the physiological and pathological 
relevance of programmed necrosis has come recently due 
to the recognition that carefully orchestrated repression 
of the programmed necrotic pathway by apoptotic regu-
latory proteins, such as FADD and caspase-8, is essential 
for proper mammalian development [5-7], and also pre-
vents spontaneous cell death and inflammation in lym-
phocytes [6-8], keratinocytes [9], and intestinal epithelial 
cells [10, 11]. In addition, programmed necrosis is now 
acknowledged to play roles in pathological processes [3, 
4, 12], including a facilitative role in tissue damage, such 
as ischemia-reperfusion injury [13], and in host defense 
of viral infections [14].
Programmed cell death can be induced by several 
stimuli, including the proinflammatory cytokine TNF-α. 
Studies of this mode of cell death often utilize the murine 
fibrosarcoma cell line L929, or the human colon adeno-
carcinoma cell line HT-29 as models. In the case of L929 
cells, TNF-α treatment alone is sufficient to trigger pro-
grammed necrosis, while in the case of HT-29 cell line, 
the addition of either SMAC mimetic or cycloheximide, 
in combination with the pancaspase inhibitor zVAD, are 
necessary to induce this type of death. 
Receptor-interacting protein kinase-3 (RIP3 or RIPK3) 
is an essential part of the cellular machinery that executes 
the programmed necrotic cell death [15-17]. Activation 
of the canonical programmed necrosis includes the for-
mation of a complex containing RIP3 and RIP1 (RIPK1) 
and recruitment of mixed lineage kinase domain-like 
protein (MLKL) [18, 19], which is essential for death to 
proceed [20, 21]. RIP3-dependent plasma membrane lo-
calization of MLKL is necessary for programmed necrot-
ic cell death, and leads to plasma membrane disruption 
either indirectly [22, 23] or directly [24, 25]. 
 Here we show that effective cytotoxic chemotherapy 
is facilitated by RIP3-dependent programmed necrotic 
cell death; however, RIP3 expression is often silenced 
in cancer due to genomic methylation near the RIPK3 
transcription start site (TSS). We show that a majority of 
cancer cell lines lack RIP3 expression due to this silenc-
ing mechanism, and loss of RIP3 expression in these cell 
lines leads to greater resistance not only to death recep-
tor ligands, but also to a surprising diversity of standard 
chemotherapeutic agents, such as DNA-damaging agents 
and taxanes. Treatment of cells with hypomethylating 
agents restores RIP3 expression and thereby promotes 
sensitivity to chemotherapeutics in a RIP3-dependent 
manner. Lastly, in > 85% of breast cancer patients, RIP3 
expression is reduced in cancer tissue samples compared 
to normal breast tissue from the same patients, suggest-
ing that deficiency of RIP3 in tumor cells is positively 
selected during tumor development and/or growth. Since 
hypomethylating agents are reasonably well-tolerated 
in patients, an implication of our study is that RIP3-de-
ficient cancer patients may benefit from receiving hy-
pomethylating agents to induce RIP3 expression prior to 
treatment with conventional chemotherapeutic agents. 
Results
RIP3 contributes to chemosensitivity
RIP3 is essential for programmed necrosis [15-17]. 
Consistent with the literature, cells lacking RIP3 expres-
sion are completely resistant to prototypical programmed 
necrotic stimuli (TNF-α + zVAD + either cycloheximide 
or SMAC mimetic; hereafter referred to as TCZ or TSZ), 
but become sensitive when RIP3 is ectopically expressed 
(Supplementary information, Figure S1A), while cells 
endogenously expressing RIP3 lose their sensitivity to 
necrotic stimuli when RIP3 is knocked down (Supple-
mentary information, Figure S1B-S1D). RIP3 kinase 
activity is essential for TNF-induced necrosis (Supple-
mentary information, Figure S1E). 
Except a possible contribution to caspase activation 
downstream of etoposide [26], a role for RIP3 in cell 
death induced by standard chemotherapeutic cytotox-
ic agents has never been reported. In HeLa, MDA-
MB231, and Huh-7 cells (which lack endogenous RIP3 
expression), the ectopic expression of RIP3 bestowed 
additional sensitivity both to etoposide and doxorubicin 
as measured by multiple assays (Figure 1A and Supple-
mentary information, Figure S2A and S2B). Conversely, 
in HT-29 cells, which have endogenous RIP3 expression, 
knockdown of RIP3 inhibited doxorubicin and etoposide 
cytotoxicity (Figure 1B and Supplementary information, 
Figure S2C). Surprisingly, ectopic RIP3 expression also 
increased sensitivity to paclitaxel, camptothecin (CPT), 
cisplatin, and 5-fluorouracil (5-FU) in multiple cell types 
(Figure 1C and data not shown). Taken together, these 
data suggested that RIP3 contributes to the cytotoxicity 
of multiple drugs with diverse mechanisms of action.
DNA-damaging agents activate RIP3-dependent 
programmed necrotic cell death
We sought to investigate the mechanism by which 
cells were sensitized to chemotherapeutics by RIP3. We 
first examined whether RIP3 was in the same complex 
as caspase-8 upon treatment of cells with etoposide and 
doxorubicin. These agents led to interaction of caspase-8 
with RIP1 and RIP3, along with FADD, though no in-
Gi-Bang Koo et al.
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Figure 1 Expression of RIP3 contributes to sensitivity to DNA-damaging agents. (A) HeLa, MDA-MB231, and Huh7 cells 
ectopically expressing RIP3 were treated with the indicated concentration of doxorubicin or etoposide for 2 days and cell 
viability was analyzed by MTT assay (right). Results are presented as means ± SEM. (B) HT-29 cells with stable shRNA 
expression were analyzed by western blotting (left). Cells were treated with doxorubicin or etoposide for 48 h and cell via-
bility was analyzed by MTT assay (right). Results are presented as means ± SEM. (C) Huh7 cells from A were treated with 
doxorubicin (Doxo, µM), etoposide (Etopo, µM), taxol (nM) , 5-fluorouracil (5-FU, µM), camptothecin (CPT, µg/ml), or cisplatin 
(µM), as indicated, and after 48 h, cell viability was analyzed by MTT assay. Results are presented as means ± SEM. (D) 
HT-29 cells were pretreated with the RIP3 inhibitor dabrafenib (10 µM) for 1 h and then treated with TCZ/TSZ, doxorubicin, 
or etoposide for 48 h. Cell viability was analyzed by MTT assay. Results are presented as means ± SEM. (E) Inhibition 
of downstream event of RIP3 kinase activation affects cell death in response to DNA-damaging agents. HeLa and RIP3-
expressing HeLa cells were pretreated with dabrafenib (10 µM) or NSA (1 µM) for 1 h and then treated with TCZ/TSZ or 
doxorubicin (1 µM) for 24 h. Cell viability was analyzed by MTT assay. Results are presented as means ± SEM. *P < 0.05, 
**P < 0.01, ***P < 0.001.
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teraction was detected in untreated cells (Supplementary 
information, Figure S2D). Unexpectedly, TRADD, a 
component of TNF-R1 signaling, was also found in the 
complex (Supplementary information, Figure S2D). 
We therefore investigated whether autocrine produc-
tion of TNF-α contributed to cell death. However, an 
antagonistic TNF-R1 antibody had no effect on doxo-
rubicin-induced cell death despite its ability to prevent 
TNF-R1-stimulated IκBα degradation, JNK activation, 
and cell death (Supplementary information, Figure S2E). 
In addition, knocking down TNF-R1 by shRNA did not 
reduce toxicity in response to doxorubicin, though it 
reduced TSZ-induced cell death (Supplementary infor-
mation, Figure S2F). Complexes containing RIP1, RIP3, 
FADD, and caspase-8 can contribute directly to apoptosis 
through caspase-8 activation (ripoptosome) or activate 
programmed necrosis through RIP3 kinase activity and 
the phosphorylation of MLKL (necrosome). However, 
the kinase activity of RIP3 is not thought to contribute to 
caspase activation [27, 28]. We therefore sought to de-
termine whether the kinase activity of RIP3 contributes 
to chemocytotoxicity. The stable ectopic expression of 
wild-type (WT) RIP3 sensitized the RIP3−/− mouse em-
bryonic fibroblasts (MEFs) to doxorubicin and etoposide, 
while kinase-dead RIP3 failed to do so (Supplementary 
information, Figure S2G). Thus, while RIP3 is not abso-
lutely required for cell death, RIP3 increases chemosen-
sitivity in a kinase-dependent fashion. 
Endogenous RIP3 was observed to interact with 
endogenous RIP1 in response to doxorubicin (Supple-
mentary information, Figure S3A), and sustained JNK 
activation, which often accompanies programmed ne-
crosis [29, 30], was elevated in RIP3-expressing cells in 
response to cisplatin, CPT, and doxorubicin compared to 
RIP3-deficient cells (Supplementary information, Figure 
S3B-S3D). Though RIP3 was reported to contribute to 
caspase activation [26], the above data suggested that 
programmed necrosis might be important for RIP3-depen-
dent chemocytotoxicity. To further test this hypothesis, 
we used three pharmacological inhibitors of programmed 
necrosis, necrostatin-1, necrosulfonamide and dabrafenib. 
Of these inhibitors, necrostatin-1 inhibits RIP1 kinase ac-
tivity [31]; dabrafenib inhibits RIP3 kinase activity [32]; 
while necrosulfonamide inhibits MLKL functions down-
stream of RIP3 phosphorylation [24]. Necrostatin-1 and 
necrosulfonamide were substantially better at protecting 
HT-29 cells from the acute toxicity of etoposide than 
the pancaspase inhibitor zVAD, which had little effect 
on cell death (Supplementary information, Figure S4A). 
Dabrafenib, which fully inhibited TSZ- and TCZ-induced 
necrosis (Figure 1D and 1E), also inhibited both etopo-
side- and doxorubicin-induced cell death in HT-29 cells, 
though to a lesser extent (Figure 1D and Supplementary 
information, Figure S4B). Likewise, in RIP3-expressing 
HeLa cells, necrosulfonamide and dabrafenib inhibited 
doxorubicin- and etoposide-induced cell death (Figure 
1E and Supplementary information, Figure S4C), but had 
no effect in parental HeLa cells lacking RIP3 expression, 
suggesting that RIP3 contributed to cell death through 
programmed necrosis. 
MLKL is activated by DNA-damaging agents and is 
required for RIP3-dependent cell death
In HT-29 cells, MLKL phosphorylation is observed 
during TNF-induced necrosis (TCZ), but not TNF-in-
duced apoptosis (TC; Supplementary information, Figure 
S4D), and is inhibited by necrostatin-1 and dabrafenib 
(Supplementary information, Figure S4E), but not 
necrosulfonamide ([24], data not shown). In HeLa cells, 
TSZ induces MLKL phosphorylation only when RIP3 
is expressed (Supplementary information, Figure S4F). 
Importantly, doxorubicin also induced dose- and time-
dependent MLKL phosphorylation in RIP3-HeLa cells 
(Figure 2A and 2B), but not in parental HeLa cells (Fig-
ure 2A and Supplementary information, Figure S4G). 
However, p53 stabilization was detected in both parental 
HeLa and RIP3-HeLa cells (Figure 2A and Supplemen-
tary information, Figure S4G). Like doxorubicin, etopo-
side induced MLKL phosphorylation in RIP3-HeLa and 
HT-29 cells (Figure 2B and Supplementary information, 
Figure S4H). Phospho-MLKL colocalized with RIP3 in 
doxorubicin- and etoposide-treated cells, similar to the 
colocalization pattern seen during TNF-induced necrosis 
(Figure 2C). Furthermore, ectopic and endogenous RIP3 
could be co-immunoprecipitated with MLKL after doxo-
rubicin treatment in HeLa and HT-29 cells, respectively 
(Figure 2D and 2E, Supplementary information, Figure 
S4I). Doxorubicin-induced MLKL phosphorylation was 
inhibited by dabrafenib, but not by necrosulfonamide 
(Supplementary information, Figure S4J), consistent 
with their mechanisms of inhibition during TNF-in-
duced necrosis. Significantly, MLKL knockdown in 
either RIP3-HeLa or HT-29 cells inhibited doxorubicin 
or etoposide cytotoxicity (Figure 2F and 2G, Supple-
mentary information, Figure S4K), suggesting that RIP3 
promotes cell death through activation of MLKL-depen-
dent programmed necrosis.
RIP3 is silenced in many cancer cell lines, but not in 
normal cells, through methylation-dependent mechanisms
While the above data indicate that programmed necro-
sis contributes to chemotherapeutic cytotoxicity, many 
cancer cell lines are resistant to programmed necrosis 
induced by TNF and other stimuli. RIP3 protein is absent 
Gi-Bang Koo et al.
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Figure 2 MLKL phosphorylation induced by DNA-damaging agents is dependent on RIP3 kinase activity. (A) HeLa and 
RIP3-expressing HeLa cells were treated with different concentrations of doxorubicin for 24 h and cell lysates were analyzed 
by western blotting. (B) RIP3-expressing HeLa cells were treated with doxorubicin (0.5 µM) or etoposide (12.5 µM) for the 
indicated times and cell lysates were analyzed by western blotting. (C) HeLa cells were transiently transfected with GFP-
hRIP3 and cells were treated with TCZ, doxorubicin (0.5 µM), and etoposide (12.5 µM) for the indicated times. Cells were 
stained with phospho-MLKL antibody and analyzed by confocal fluorescence microscopy. Scale bar, 10 µm. (D) HeLa and 
RIP3-expressing HeLa cells were treated with doxorubicin (1 µM) for 12 h and cell lysates were immunoprecipitated with 
anti-MLKL antibody. (E) HT-29 cells were treated with doxorubicin (1.25 µM) for 24 h. Cell lysates were immunoprecipitated 
with anti-MLKL antibody and analyzed by western blotting for RIP3. The asterisk (*) indicates the IgG band. §The upper band 
in this blot is thought to be phosphorylated RIP3, and appears only in the doxorubicin-treated cells. (F, G) RIP3-expressing 
HeLa (F) or HT-29 cells expressing MLKL shRNAs or non-silencing control (G) were analyzed by western blotting (insets). 
Cells were treated with TSZ, doxorubicin, or etoposide for 48 h and cell viability was analyzed by MTT assay. Results are 
presented as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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in about two-thirds of the 60+ cancer cell lines that we 
have tested. While only 20% of examined hematopoetic 
cell lines lack RIP3 expression, 80% of the other cell 
lines have no detectable RIP3 (Figure 3A). In contrast, 
RIP3 is expressed in primary cells and most normal tis-
sues, as well as in some non-transformed cell lines, as 
measured by western blotting or immunohistochemical 
staining in paraffin-embedded specimens (Figure 3B and 
Supplementary information, S5A and S5B), indicating 
that RIP3 deficiency could be associated with cancer 
development or progression. We therefore sought to de-
termine the mechanism(s) responsible for RIP3 deficien-
cy in cancer cells. Protein insolubility did not contribute 
to lack of RIP3 detection (Figure 3C). Unlike the protein 
NIK, which is constitutively degraded by the proteosome, 
inhibition of proteosome function by MG132 did not 
lead to increased RIP3 (Figure 3D), suggesting that lack 
of RIP3 expression is not due to constitutive protein 
turnover. 
We examined whether DNA methylation or histone 
deacetylation was responsible for RIP3 deficiency. 
HDAC inhibitors TSA and sodium butyrate did not affect 
RIP3 expression in HeLa cells on their own. However, 
treatment with the hypomethylating agent decitabine 
(5-aza-2′-deoxycytidine, abbreviated as 5-AD) restored 
RIP3 expression (Figure 3E). In multiple cell lines, 5-AD 
induced RIP3 expression in a time- and dose-dependent 
manner (Figure 3F). Approximately 70% of tested cell 
lines responded to 5-AD by upregulating RIP3 protein 
(Figure 4A), suggesting that methylation-dependent 
RIP3 silencing is prevalent. Mouse cancer cell lines also 
responded to 5-AD by upregulating RIP3 (Supplementa-
ry information, Figure S5C and S5D). RIP3 mRNA was 
largely absent in cells lacking RIP3 protein; however, 
5-AD upregulated RIP3 mRNA in a manner similar to 
sFRP2 (Figure 4B), a protein previously shown to be 
silenced by promoter methylation [33]. Treatment with 
5-AD did not affect RIP3 mRNA or protein in cells al-
ready expressing RIP3 (Supplementary information, Fig-
ure S5E and S5F). RIP3 mRNA and protein expression 
were similarly induced by other hypomethylating agents, 
including 5-azacytidine (5-AZA) and RG108 (Figure 4C 
and 4D, Supplementary information, Figure S5G and 
S5H). 
Our analysis of RIPK3 methylation from the publicly 
available databases (such as the University of Califor-
nia-Santa Cruz Genome Browser, among others), com-
bined with analysis of our RIP3 protein expression data, 
suggested that the correlation between RIP3 silencing 
and the methylation of a given CpG is strongest very 
near the TSS, and is much reduced a few hundred base-
pairs downstream of the TSS. These databases suggest 
that a CpG island exists about 240-600 bp downstream 
of the TSS. Therefore, these CpGs would be considered 
to be on the “northern CpG island shore”. CpG island 
shore methylation has been shown to be sometimes 
strongly related to gene expression, even more so than 
the islands themselves [34]. Therefore, we sought to 
investigate whether methylation of this region was re-
sponsible for RIP3 silencing. Not surprisingly, methyl-
ation-specific PCR indicated that methylation occurred 
in this region of genomic DNA near the TSS of RIPK3 
in RIP3-silenced cells (MDA-MB231, K562, HeLa), but 
not in RIP3-expressing HT-29 cells (Figure 4E). Further 
methylation-specific PCR using multiple primer sets in 
several different cell lines indicated that the methylation 
of RIPK3 genomic DNA was responsive to 5-AD (Figure 
4F), and methylation status inversely corresponded to 
mRNA and protein expression in these cell lines under 
treated and non-treated conditions (compare Figure 4F to 
Figures 3A, 3F, 4A and 4B). 
To verify that the expression of RIP3 was associat-
ed with methylation of genomic DNA near the TSS of 
RIPK3, we conducted pyrosequencing of individual 
CpGs in bisulfate-converted DNA within this region in 
multiple cell lines treated or untreated with 5-AD (Sup-
plementary information, Figure S6A and S6B). Analysis 
of these experiments suggested that silencing of RIP3 
expression was especially associated with four proximal 
CpGs just downstream of the RIP3K TSS. Cells that 
were resistant to 5-AD in terms of RIP3 reexpression (i.e., 
MDA-MB468 and A549N) responded minimally in terms 
of reduction of methylation in any sequenced CpGs. On 
the other hand, HT-29 cells, which express RIP3 highly, 
had very low methylation of the entire region.
To examine the role of methyltransferases in RIP3 si-
lencing, we knocked down maintenance methyltransfer-
ase, DNMT1. DNMT1 knockdown led to RIP3 mRNA 
expression (Figure 4G). Furthermore, 5-AD treatment 
led to the loss of DNMT1 protein (Figure 4H and Sup-
plementary information, Figure S7A), consistent with 
proteosomal degradation of inhibited DNMT1, which 
has been previously observed following treatment with 
hypomethylating agents [35]. In contrast, the expression 
of DNMT3a protein was only slightly reduced by 5-AD 
(Supplementary information, Figure S7A). The mRNA of 
DNMT1 also seemed to be reduced in HeLa and DLD-
1 cells in the presence of 5-AD; however, DNMT3a 
and DNMT3b expression was not reduced after 5-AD 
treatment (Supplementary information, Figure S7B). In 
addition, HT-29 cells, which express endogenous RIP3, 
had very little, if any, DNMT1 mRNA (Supplementary 
information, Figure S7B). RIP3 mRNA was upregulat-
ed in response to knockdown of DNMT1; however, the 
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Figure 3 RIP3 is silenced by methylation in multiple cancer cell lines. (A) Western blotting analysis of lysates from multiple 
cancer cell lines showing RIP3 expression. (B) Western blotting analysis of RIP3 expression is shown in melanocyte, 
keratinocyte and fibroblasts from human normal skin. Other lysates from human mammary epithelial cells (HMLE: 
immortalized, hTERT + T antigens; HME: primary), primary prostate epithelial cells (two specimens: PPE7, PPE30), normal 
hepatocyte cell line HL7702 and primary brain tissue (two specimens: E3, E37) were also probed for RIP3 expression. (C) 
HeLa, A549, and HT-29 cells were either lysed in M2 buffer (left) or directly dissolved and boiled in Laemmli SDS buffer (right) 
and lysates were analyzed by western blot. Blotting for Vimentin is included as a positive control for detection of insoluble 
protein. (D) Immunoblotting showing NIK protein expression in HeLa and DLD-1 cells upon proteosome inhibition with MG132 
(10 µM). (E) Western blotting analysis of HeLa cells treated with sodium butyrate (2.5 mM) or Trichostatin A (0.25 µg/ml) for 1 
day in the presence or absence of 5-AD. (F) Western blotting analysis of RIP3 expression in HeLa, MDA-MB231, and DLD-1 
cells treated with 5-AD for the indicated times (2 µM) and with different concentrations (4 days). 
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Figure 4 Methylation of the RIP3K TSS is negatively associated with RIP3 expression in cancer cell lines. (A) Western 
blotting showing the response of various cancer cells to 5-AD (2 µM, 4 days). (B) Reverse transcription-PCR products from 
cells following treatment with 5-AD (2 µM, 4 days). A sFRP2 product is shown as a positive control for methylation. (C) 
Western blotting and reverse transcription-PCR results after 5-AZA treatment of HeLa (0.625 µM, 8 days) or DLD-1 (1.25 µM, 
4 days) cells. (D) Western blotting and reverse transcription-PCR results after treatment of HeLa cells with 5-AD (2 µM, 4 
days) or RG108 (100 µM, 8 days). (E) Methylation-specific PCR (MSP) of genomic DNA from HeLa, MDA-MB231, K562, and 
HT-29 cells. M and U indicate methylated-specific and unmethylated-specific primers, respectively, to the RIPK3 sequence. (F) 
MSP of genomic DNA from HeLa, DLD-1, HCT-116, MDA-MB231, and K562 cells treated with 5-AD (2 µM, 4 days). MSP was 
repeated on genomic DNA from HeLa and DLD-1 cells with a second set of methylated- and unmethylated-specific primers. (G, 
H) HeLa and DLD-1 cells were infected with a lentivirus encoding DNMT1 shRNAs, or non-silencing control. After selection 
with puromycin, cells with stable shRNA expression were analyzed by reverse transcription-PCR (G) or western blotting (H) 
after 5-AD (2 µM) treatment of HeLa or DLD-1 cells, showing reverse correlation between DNMT1 and RIP3 expression.
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knockdown of DNMT3a or DNMT3b did not result in 
increases in RIP3 mRNA either alone or when used in 
combination with DNMT1 knockdown (Supplementary 
information, Figure S7C-S7E). Interestingly, when A549 
or A549-N cells were treated with 5-AD, there was no 
observable loss in DNMT1 mRNA in A549-N cells as 
in A549 cells, consistent with their lack of response to 
5-AD (Supplementary information, Figure S7F). When 
DNMT1 was overexpressed in H2009 cells, which have 
endogenous RIP3 expression, RIP3 expression was sig-
nificantly reduced (Supplementary information, Figure 
S7G). The DNA methylation data, the response of RIP3 
expression to 5-AD, and the reverse correlation between 
DNMT1 and RIP3 protein expression, suggest that 
DNMT1 is the methyltransferase that is responsible for 
maintaining RIP3 silencing in cancer cell lines.
Methylation of the genomic region near the TSS of 
RIPK3 regulates RIP3 expression in human AML patients
RIP3 is not frequently silenced in hematopoetic can-
cer cell lines (Figure 3A), thus RIP3 methylation is not 
expected to be prevalent in blood-related cancers. Never-
theless, we examined samples from patients with AML, a 
disease often characterized by aberrant methylation and 
sometimes treated with hypomethylating agents. RIP3 
was expressed significantly at protein levels in the blood 
of non-cancer patients; however, bone marrow obtained 
from four of nine AML patient samples had low RIP3 
protein and mRNA expression (Supplementary informa-
tion, Figure S8A and S8B). This largely corresponded 
to the level of methylation downstream of the RIPK3 
TSS in these patients; all patients with a methylated/
unmethylated DNA ratio > 50% had low expression 
of RIP3 (Supplementary information, Figure S8B and 
S8C). When we examined the expression of DNMTs 
in these patients (Supplementary information, Figure 
S8D), DNMT1 was somewhat correlated with the RIPK3 
methylation status (Supplementary information, Figure 
S8E). In one AML clinical trial in which we were able 
to obtain PBMC samples before and after treatment (5-
AZA and lenolidomide), we found only one patient with 
low RIP3 mRNA expression. RIP3 mRNA in this patient 
was significantly increased in the post-treatment sample, 
indicating response to the hypomethylating agent (Sup-
plementary information, Figure S8F). MethylCap-se-
quencing in a separate group of 10 AML patients indicat-
ed that the detectable RIPK3 methylation of four patients 
was eliminated in response to 5-AD treatment, while one 
patient gained methylation after treatment (Supplemen-
tary information, Figure S8G). Thus, despite that AML is 
likely a suboptimal cancer type to examine RIP3 silenc-
ing, the AML data provide proof of principle that RIPK3 
methylation controls RIP3 expression in human patients, 
and that hypomethylating agents could potentially be 
used to manipulate RIPK3 methylation and expression in 
vivo.
RIP3 expression is lost in primary breast cancers
We next examined RIP3 expression in primary breast 
cancer samples by immunoblotting. Approximately 
80% of the patients had significantly less expression of 
RIP3 protein in tumor samples than normal tissue (Fig-
ure 5A). Immunohistochemical (IHC) analysis of RIP3 
gave similar results to western blotting (Figure 5B), and 
mRNA expression was correlated with protein expres-
sion (Supplementary information, Figure S9A). In IHC 
data from 75 breast cancer patients, RIP3 was reduced 
in tumor compared to normal tissue, with many tumors 
lacking detectable RIP3 (see Supplementary informa-
tion, Figure S9B for scoring comparisons between paired 
samples; Figure 5B, right panel, for average histological 
scoring). All cancer subtypes had decreased expression 
of RIP3, with luminal A (73%) and luminal B (84%) sub-
types slightly less likely to be RIP3 deficient than triple 
negative (90%) and Her2-positive (95%) cancers (Figure 
5C), and as a group, ER-positive tumors were slightly 
less likely to be RIP3 deficient than ER-negative tumors 
(Supplementary information, Figure S9C). Methylation 
of the genomic region near the RIPK3 TSS was increased 
in tumor compared to normal samples, showing that RIP3 
deficiency was correlated with methylation (Figure 5D). 
We would expect that the few patients with tumor RIP3 
expression could respond better to chemotherapy than 
their counterparts, and therefore have better outcomes. 
Unfortunately, many gene expression arrays previously 
used in breast cancer outcome studies lacked RIP3 probe 
sets. However, using the bc-GenExMiner tool designed 
by Jézéquel et al. [36], we analyzed combined data avail-
able from 6 studies (1 166 patients). Patients with greater 
than median RIP3 mRNA expression had a higher prob-
ability (P < 0.0085) of metastatic relapse-free survival 
over a 10-year period (Figure 5E). Unfortunately, this 
tool groups the patients only into two groups above and 
below the median (50% split), rather than in quartiles or 
other smaller divisions. Because RIP3 expression is very 
low in > 85% of tumors (Supplementary information, 
Figure S9B), this means that ~30% of patients that have 
low RIP3 expression are wrongly classified into the up-
per 50% curve as RIP3 proficient, thus the upper curve 
of the Kaplan-Meier plot contains many patients that are 
RIP3 deficient, and the plot underestimates the prognosis 
for the breast cancer patients that have normal RIPK3 
expression. 
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Hypomethylating agents restore programmed necrosis in 
cancer cells through reversal of RIP3 silencing
 The response of cells to 5-AD suggests that RIP3 
expression may be manipulated in cancer cells to make 
them sensitive to programmed necrosis. When treated 
with 5-AD, multiple cell types previously refractory to 
TNF-α-induced necrosis became sensitive (Supplemen-
tary information, Figure S10A-S10C). This was accom-
panied by sustained activation of JNK (Supplementary 
information, Figure S10D), which is often associated 
with programmed necrosis [29, 30], and RIP3 was found 
in association with RIP1 in the necrosome complex 
(Supplementary information, Figure S10E). Importantly, 
5-AD did not sensitize RIP3-expressing HT-29 and L929 
cells to TNF-α-induced necrotic cell death (Supplemen-
tary information, Figure S11A). Moreover, while 5-AD 
sensitized A549 cells to TNF-induced necrosis, a variant 
of A549 (designated A549-N) that upregulates sFRP2 but 
not RIP3 in response to 5-AD, remained resistant (Sup-
plementary information, Figure S11B). Notably, other 
hypomethylating agents that restored RIP3 expression 
similarly sensitized HeLa cells to TNF-α-induced necro-
sis (Supplementary information, Figure S11C). Signaling 
pathways downstream of death receptor activation were 
minimally affected by 5-AD, since TNF-α- or TRAIL-in-
duced IκBα degradation and transient JNK phosphoryla-
tion remained normal (Supplementary information, Figure 
S11D). Multiple shRNAs preventing RIP3 upregulation 
blocked 5-AD-mediated sensitization to TNF-α-induced 
necrosis (Supplementary information, Figure S11E) and 
RIP3 shRNA inhibited TNF-α-induced necrosis in HT-
29 cells to a similar extent irrespective of whether or not 
5-AD was present (Supplementary information, Figure 
S11F). These data collectively indicate that hypomethyl-
ating agents restore TNF-α-induced programmed necro-
sis in cancer cells solely through reversal of RIP3 silenc-
ing and not through additional mechanisms.
Hypomethylating agents sensitize RIP3-deficient cells to 
chemotherapeutic agents in a RIP3-dependent manner
We next sought to test whether hypomethylating 
agents would sensitize RIP3-deficient cells to chemother-
apeutic agents via restoration of RIP3 expression. 5-AD 
treatment sensitized multiple RIP3-deficient cell lines 
both to etoposide and to doxorubicin, as measured by 
multiple assays (Figure 6A and 6B, Supplementary infor-
mation, Figure S12A-S12F), and 5-AZA similarly sen-
sitized multiple cell lines to doxorubicin and etoposide 
(Supplementary information, Figures S12F, S13A and 
S13B), as well as CPT and actinomycin D (Supplementary 
information, Figure S13A, right panel). Hypomethylating 
agents also sensitized RIP3-deficient cell lines to other 
drugs, including paclitaxel, 5-FU, CPT, and cisplatin 
(Supplementary information, Figure S13C and S13D; 
data not shown), similar to the experiments in cells with 
ectopic RIP3 expression (Figure 1C). 
Importantly, 5-AD failed to sensitize RIP3-expressing 
HT-29 cancer cells and HDF normal cells to the doxo-
rubicin and etoposide, as well as other drugs (Figure 
6C and 6D). Likewise, 5-AD failed to chemosensitize 
RIP3−/− MEFs (Supplementary information, Figure 
S13E) as well as A549-N cells (Figure 6E), which up-
regulated sFRP2 but not RIP3 in response to 5-AD 
(Supplementary information, Figures S11B, S6B and 
S7F). Thus 5-AD appeared to act through induction of 
RIP3 expression. Crucially, RIP3 shRNA inhibited 5-AD 
potentiation of doxorubicin- and etoposide-induced cell 
death in HeLa cells (Figure 6F). Likewise, 5-AD and 
5-AZA potentiation of doxorubicin toxicity was inhibited 
by RIP3 shRNA in K562 cells (Supplementary informa-
tion, Figure S14A and S14B). In the absence of RIP3, 
5-AD also lost its ability to sensitize MDA-MB231 cells 
to multiple chemotherapeutic agents as measured by 
different assays (Figure 6G and Supplementary informa-
tion, Figure S14C), confirming that their sensitization is 
Figure 5 RIP3 is silenced in breast cancer. (A) Western blotting for RIP3 expression is shown for breast cancer tumors 
compared to normal tissue from the same patients (N, normal tissue; T, tumor tissue). In 3 cases where the actin immunoblots 
had problems, ERK protein is shown as a protein loading control. (B, C) Immunohistochemical staining of RIP3 in paraffin-
embedded tissue specimens from tumor and non-tumor samples in breast cancer patients. Arrows indicate entrapped normal 
ducts. Paired tumor and normal tissue from each patient was quantitated (B, right). Intensity of histological staining grade 
was quantitated according to American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guide-
lines using the following categories: 0, no immunostaining; 1+, weak incomplete membranous staining, < 10% of tumor cells; 
2+, complete membranous staining, either uniform or weak in at least 10% of tumor cells; and 3+, uniform intense membra-
nous staining in at least 30% of tumor cells. Staining grade is shown for various subtypes of breast cancer (C). Scale bar, 100 
µm. (D) Methylation-specific PCR of genomic DNA from tumor and non-tumor tissue of three triple-negative breast cancer 
patients (patients A-C). M and U indicate methylated-specific and unmethylated-specific primers (set 1), respectively, to the 
RIPK3 genomic sequence. (E) Kaplan-Meier curve showing metastasis relapse (MR)-free survival of breast cancer patients 
having above or below median expression of RIP3 (RIPK3). Hazard ratio (HR) based on relative risk of event occurrence 
between the group of patients with RIP3 expression above the median value in the selected population and the group with 
RIP3 expression below the median value.
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Figure 6 Restoration of RIP3 by hypomethylating agents enhances sensitivity to DNA-damaging agents. (A, B) HeLa and 
MDA-MB231 cells were treated with 5-AD (2 µM, 4 days), then with doxorubicin or etoposide for 48 h and cell viability 
was analyzed by MTT assay (A) or ATP depletion (B). Results are presented as means ± SEM. (C-E) HT-29 cells, which 
endogenously express RIP3, were treated with 5-AD (2 µM, 4 days) and then with doxorubicin or etoposide for 48 h, and 
cell viability was analyzed by MTT assay (C). Human dermal fibroblasts (HDF), which are untransformed and have RIP3 
expression, were treated with 5-AD (2 µM, 4 days), then with doxorubicin (2 µM), etoposide (25 µM), 5-FU (50 µM), or CPT 
(1 µg/ml) for 48 h and cell viability was analyzed by MTT assay (D). A549-N cells, which do not upregulate RIP3 expression in 
response to hypomethylating agents, were treated with 5-AD (2 µM) for 4 days and cell viability was analyzed by MTT assay 
(E). Results are presented as means ± SEM. (F) HeLa cells with stable shRNA expression were pretreated with 5-AD (2 µM, 
4 days) and then treated with doxorubicin or etoposide for 2 days and cell viability was analyzed by MTT assay. Results are 
presented as means ± SEM. (G) MDA-MB231 cells with stable shRNA expression were pretreated with 5-AD (2 µM) for 4 days 
and then treated with doxorubicin (µM), etoposide (µM), CPT (µg/ml), and cisplatin (µM) for 48 h and cell viability was ana-
lyzed by relative ATP level analysis. Results are presented as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
dependent on the induction of RIP3 expression. Taken 
together, these data suggest that hypomethylating agents 
promote chemosensitivity in these cell types largely 
through the induction of RIP3 expression.
5-AD synergizes with doxorubicin in breast tumor 
treatment in vivo
Lastly, an orthotopic MDA-MB231 xenograft tumor 
model was used to examine whether 5-AD would pro-
mote chemosensitivity in vivo. Mice were treated with 
5-AD, doxorubicin, or both, with doxorubicin and 5-AD 
doses such that they had minimal effect by themselves 
on tumor growth (Figure 7A and 7B). The combination 
of 5-AD and doxorubicin resulted in a synergistic reduc-
tion in tumor size and tumor mass (Figure 7A and 7B), 
with no appreciable toxicity in the liver (Figure 7C). 
TUNEL staining and IHC staining of p-H2AX indicat-
ed a significantly greater cytotoxicity in the tumors of 
the doxorubicin/5-AD-treated mice than in the tumors 
of mice treated with a single drug (Figure 7D). RIP3 
mRNA was highly expressed in the tumors of most of the 
5-AD-treated mice, irrespective of whether or not mice 
were treated with doxorubicin (Figure 7E) and RIP3 
protein was clearly detected in tumors of doxorubicin/5-
AD-treated mice, but not untreated mice (Figure 7F). 
These data suggest that 5-AD was effective in restoring 
RIP3 expression in tumor cells in vivo, and that it can 
synergize with doxorubicin to reduce the tumor burden 
of RIP3-deficient breast cancer in vivo.
Discussion
Our data indicates that RIP3 contributes to the cyto-
toxicity of chemotherapeutic agents with disparate mech-
anisms of action, including topoisomerase inhibitors, 
taxanes, platinum complexes, anthracyclines, and anti-
metabolites through induction of programmed necrosis. 
How RIP3 is activated by drugs with such mechanistic 
differences is an important matter for future investiga-
tion. A role for RIP1 in genotoxic-induced cell death has 
been suggested in several previous publications [26, 37]. 
A RIP1-dependent complex was previously reported to 
play a role in etoposide-induced cell death through the 
activation of both apoptotosis and necrosis, however, in 
that report RIP3 was described as contributing to caspase 
activation [26] through the “ripoptosome”, a very large 
complex containing RIP1, FADD, and caspase-8, as well 
as caspase-10 and cFLIP [26, 38] that is assembled after 
treatment with IAP antagonists [38]. The ripoptosome is 
similar to the secondary complex (TNF-R1 complex II) 
formed downstream of TNF-R1 activation [39], but its 
formation does not require TNF-R1. Our data also sug-
gests the formation of a similar complex in response to 
chemotherapeutics, and we also did not observe TNF-R1 
involvement. Interestingly, TRADD was recruited to the 
complex, which suggests additional similarity to TNF-R1 
complex II, though these complexes may originate by 
different mechanisms. Since a previous report indicated 
that depletion of cIAP proteins was key to the formation 
of the ripoptosome, cIAP depletion may indicate a com-
mon mechanism for formation of this complex induced 
by chemotherapeutic drugs with different mechanisms of 
action [38]. We have not yet examined whether this is a 
common occurrence with all stimuli. However, if so, it 
remains uncertain how cIAP depletion would occur after 
treatment of all of these different drugs. JNK activation 
contributes to a common mechanism after treatment 
of all of these different agents, since JNK activity is 
known to accompany, and sometimes be required for, the 
programmed necrotic pathway in many instances [29, 
30]. However, we found that JNK activity was highly 
enhanced in RIP3-expressing cells in response to various 
chemotherapeutics, suggesting that JNK activation is 
downstream of the necrosome complex formation. 
Unlike the previous papers mentioned above, we were 
able to immunoprecipitate RIP3 with the RIP1 complex. 
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Figure 7 The combination of 5-AD plus doxorubicin inhibits breast cancer growth in a mouse xenograft model. (A) Effect 
of 5-AD plus doxorubicin on MDA-MB231 breast cancer cell xenograft in athymic BALB/c nude mice. MDA-MB231 tumors 
were established orthotopically and treated with 5-AD for the first week and then doxorubicin for 33 days. Tumor volume was 
monitored and is shown in the graph. Data are presented as means ± SD (n = 7). (B) At the end of treatment mice were killed 
and tumors are shown (left). Tumor mass was measured and is summarized (right). (C) H&E staining for liver section of mice 
receiving the indicated treatment. (D) Top panel shows detection of cell death by TUNEL assay in tumor sections of mice 
receiving the indicated treatment. Sections were also stained for p-H2AX and H&E. (E) PCR of tumor tissues to detect RIP3 
restoration upon 5-AD injection in mice. (F) Immunohistochemical staining of RIP3 in paraffin-embedded tissue specimens 
from tumor of mouse xenograft.
We found that complex formation led to MLKL acti-
vation and programmed necrosis rather than caspase-8 
activation and apoptosis. Interestingly, though caspases 
are well known to promote programmed necrotic cell 
Gi-Bang Koo et al.
721
npg
www.cell-research.com | Cell Research
death mediated by death receptors [4], zVAD did not 
potentiate the genotoxic compound-induced necrosis in 
our experiments. This may be because in the case of che-
motherapeutics, the caspase activation does not emanate 
solely from one complex, so does death receptor-mediat-
ed caspase-8 activation. Since genotoxic stress is known 
to trigger caspase-9 and caspase-3 activation downstream 
of mitochondrial permeabilization, zVAD may prevent 
the part of the cell death that is caspase dependent, lead-
ing to both potentiation and inhibition of cell death by 
zVAD.
A role for programmed necrosis in cell death result-
ing from DNA damage by alkylating agents was first 
suggested over a decade ago; however, in that context, 
the DNA repair protein poly(ADP-ribose) polymerase 
(PARP) was required for cell death [40]. Recent studies 
have suggested that multiple distinct mechanisms ex-
ist for programmed necrosis to occur [13, 41], and that 
PARP-dependent necrotic cell death, which has been 
referred to as “parthanatos”, and the RIP1-RIP3-depen-
dent process induced by TNF, which has been referred 
to as “necroptosis”, are largely separate pathways [41], 
though they both lead to programmed necrotic outcomes. 
Although necrostatin-1, necrosulfonamide or dabrafenib, 
unlike zVAD, provides protection from etoposide- and 
doxorubicin-induced cell death in our assays, this protec-
tion is not complete, suggesting that RIP3-independent 
mechanisms of programmed necrotic death could also be 
involved.
Tumor formation often selects against the expression 
of cell death proteins, and resistance to cell death is one 
of the hallmarks of a cancer cell [1]. One way by which 
expression of such a protein can be regulated is through 
methylation of its genomic DNA, thus silencing its tran-
scription. This appears to be the case with RIP3. Since 
RIP3 expression is lost in most cancer cell lines and is 
low in about 85% of primary breast cancer samples that 
we have examined, but RIP3 is present in normal tissue 
and in primary cells (Figure 4B, [42-44]), this would 
suggest that RIP3 expression is negatively selected 
during initial tumor development or tumor growth. Loss 
of RIP3 in cancer cells (or in highly passaged cell lines, 
such as non-tumorigenic MCF10A and MCF12A) is 
understandable since such cells are under strong selective 
pressure, and given the essential role of RIP3 in promot-
ing programmed necrotic cell death, loss of RIP3 may 
provide a selective advantage during growth. 
The analysis of RIPK3 methylation from our data and 
the publicly available databases (such as the University 
of California-Santa Cruz Genome Browser, among oth-
ers), combined with our RIP3 protein expression data, 
suggests that the correlation between RIP3 silencing 
and the methylation of a given CpG is strongest very 
near the TSS, and is much reduced a few hundred base-
pairs downstream of the TSS (mostly correlated with the 
methylation status of four proximal CpGs just down-
stream of the RIP3K TSS). Although we cannot exclude 
the presence of enhancer sequences within this region of 
the genome, the correlation of methylation near the TSS 
may suggest that methylation may directly interfere with 
the DNA binding of the main transcriptional machinery.
Importantly, RIP3 expression may be restored in most 
cells by use of simple hypomethylating agents, such as 
5-AD, enabling the manipulation of RIP3 expression in 
both cell lines and patients, and thus sensitization to pro-
grammed necrotic cell death. Multiple clinical trials of 
5-AZA as a single agent therapy have previously demon-
strated a response plus stable disease rate of about 35% 
in breast cancer patients, with a response rate of 18% [45]. 
While this response rate may seem small, the response 
rate for myelodysplastic syndrome (5-AZA has recently 
been FDA approved for its treatment) is only slightly 
higher at 23% [45]. Based on our data, we would predict 
that the use of hypomethylating agents, such as 5-AZA, 
would be much more effective when combined with oth-
er chemotherapeutic drugs. Since RIP3 sensitizes some 
cell types to doxorubicin and paclitaxel, both of which 
are currently used in the clinic for the treatment of breast 
cancer, we may expect hypomethylating agents to make 
these drugs more effective in the treatment of RIP3-defi-
cient breast cancers. 
Except a few cell lines utilizing ectopic expression of 
RIP3, the (mostly TNF-α-induced) study of programmed 
cell death has primarily been confined to a few cancer 
cell line models (e.g., the mouse fibroblast L929 cells (in 
which TNF-induced necrosis was first observed), a hand-
ful of cells from the hematopoietic system, MEFs, and a 
few epithelial cell lines of the gastrointestinal tract (such 
as HT-29), leaving researchers to wonder whether these 
particular cell lines were exceptional, or whether the 
mechanistic data obtained in these few cell lines is gen-
erally applicable. It appears from our data that a majority 
of cell lines may be sensitized to programmed necrosis 
by upregulating RIP3 expression with hypomethylating 
agents, suggesting a conservation of mechanism, and en-
abling further mechanistic study of programmed necrotic 
cell death in a wide variety of cell types.
In summary, our data indicate that RIP3 expression is 
likely negatively selected during cancer development or 
progression, with methylation of the genomic region near 
the RIPK3 TSS leading to RIP3 silencing. Since RIP3 
plays a greater role in response to chemotherapeutics 
than previously appreciated, we propose that hypometh-
ylating agents, in combination with standard chemother-
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TNF-α and zVAD were purchased from R&D Systems. An-
tibodies were purchased from the following sources: RIP3 and 
p-MLKL, Abcam; RIP1 and FADD, BD-Transduction Labora-
tories; DNMT1 and p53, Santa Cruz Biotechnology; Vimentin, 
histone-H3, NIK, and caspase-8, Cell Signaling; acetyl-histone-H3 
and histone-H4, Millipore; p-JNK, Invitrogen; complex-II, 
Molecular Probes; MLKL, Sigma-Aldrich. Doxorubicin, etoposide, 
paclitaxel, 5-FU, cisplatin, CPT, 5-AD, 5-AZA, and necrostatin-1 
were all purchased from Sigma-Aldrich (St Louis, MO, USA). 
MG132, RG108, necrosulfonamide, and cycloheximide were 
purchased from Calbiochem. Dabrafenib was purchased from 
Selleckchem. SMAC mimetic (LCL-161) was purchased from 
Adooq Bioscience. 
Cell culture
Cell lines were cultured as recommended by ATCC. WT and 
RIP3−/− MEF cells and their culture conditions have been previ-
ously described [15]. Murine stable cell lines (MEFs and mouse 
melanoma cells B16) were established by infection with pBOB-
Flag-mRIP3 lentivirus. HeLa cells expressing RIP3 were obtained 
from cells transfected with Flag-hRIP3 or GFP-hRIP3. RIP3-
expressing HeLa, MDA-MB231, and Huh-7 cells were from cells 
infected with pLX303-hRIP3 lentivirus.
Human breast tumor tissue preparation
Human breast tumor and paired normal samples were obtained 
from Yonsei University College of Medicine (Seoul, Korea). This 
study was approved by the Institutional Review Board (IRB) at 
Yonsei University, and in all cases, informed written consent was 
obtained from all participants. 
Normal human cells
Normal primary prostate (PPE) and mammary epithelial cells 
(HME) were originally obtained from Clonetics (San Diego, CA, 
USA). HMLE are normal mammary epithelial cells that have 
been immortalized with hTERT and also retrovirally-infected with 
SV40 large and small T antigens. Normal human melanocytes, 
keratinocytes and skin fibroblasts were obtained from Gibco/Life 
Technologies (Grand Island, NY, USA). Primary patient brain 
samples were obtained from Children’s Hospital Colorado and 
collected in accordance with local and federal human research 
protection guidelines and institutional review board regulations 
(COMIRB 95-500). Informed consent was obtained for all speci-
mens collected.
AML patient samples
AML patient samples obtained from the University of Colorado 
were obtained with the informed written consent from all 
participating subjects (COMIRB 06-0720). Bone marrow aspirate 
was collected in heparin or EDTA tubes. The samples were diluted 
4× with PBS before the addition of Ficoll-Hypaque (Sigma-
Aldrich) density gradient. After centrifugation, the plasma and 
mononuclear layers were collected and stored at −80 °C.
Lentiviral shRNA experiments
MISSION short-hairpin RNA plasmids targeting hRIP3 
mRNA (NM_006871), mRIP3 mRNA (NM_019955), hDNMT1 
(NM_001379), and hMLKL mRNA (NM_152649), hTNF-R1 
mRNA (NM_001065.3) and non-targeting control (NM_027088) 
were from Sigma-Aldrich. Lentiviral plasmids were transfected 
into 293TN cells (System Biosciences, LV900A-1) using Lipofect-
amine 2000 (Invitrogen). Pseudoviral particles were collected 2 
days after lentiviral plasmid transfection, and infected cells in the 
presence of polybrene (8 µg/ml). Cells were selected with puromy-
cin 2 days after infection, and RIP3 knockdown was confirmed by 
immunoblotting. Cells without endogenous RIP3 were afterwards 
treated with 5-AD for 4 days and analyzed by immunoblotting.
Western blot and co-immunoprecipitation
Cell lysis was carried out in M2 buffer [29]. Equal amounts 
of cell extracts were resolved by SDS-PAGE and analyzed by 
immunoblotting. For immunoprecipitation, lysates were mixed 
and precipitated with antibody and protein A-sepharose or protein 
G-agarose beads overnight at 4 ºC. Bound proteins were removed 
by boiling in SDS buffer and resolved by SDS-PAGE for immu-
noblotting. Human breast cancer tissues and normal tissues were 
lysed in M2 buffer, resolved by SDS-PAGE, and analyzed by im-
munoblotting and blots were visualized by enhanced chemilumi-
nescence (ECL, Amersham).
Confocal microscopy
Cells were seeded in a coverglass slide chamber after the des-
ignated treatments, fixed for 10 min in 4% paraformaldehyde, and 
then stained with p-MLKL antibody (1:250). Cells were mounted 
with 10 mg/ml DAPI in aqueous mountant (Dako, Denmark) and 
viewed by confocal microscopy. 
Cytotoxicity assays
Cell viability was determined using tetrazolium dye colorimet-
ric test (MTT and MTS (Promega) assays with absorbance read at 
570 nm and 490 nm, respectively). Cell survival assays were per-
formed using the CellTiter-Glo Luminescent Cell Viability Assay 
kit (Promega, G7570) according to the manufacturer’s instructions. 
Luminescence was measured using a POLARstar OPTIMA. For 
CellTiter-Glo assays, the mean ± STDEV of duplicates is present-
ed. 
Real-time PCR
Quantitative RT-PCR was performed in Cycler (Applied Bio-
systems, Foster City, CA, USA) with QuantiTect SYBR Green 
PCR Kit (Qiagen, Valencia, CA, USA), essentially as described in 
the manufacturer’s instructions, using specific set of primers for 
RIP3 (PPH15378B, Qiagen). Expression was normalized to SDHA 
expression (PPH20936F, Qiagen). The relative value of specific 
mRNAs in each sample was expressed as a reciprocal ratio of the 
Ct values of each message to those of the corresponding SDHA.
Reverse transcription-PCR
RNA was extracted using RNeasy (Qiagen). 200 ng of total 
RNA from each sample was used for cDNA synthesis with reverse 
transcriptase (Invitrogen). Equal amounts of cDNA product were 
used for PCR with Taq DNA polymerase (Takara). Amplification 
was performed using the following primers:
RIP3 sense (5′-CAAGGAGGGACAGAAATGGA-3′) , 
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RIP3 antisense (5′-GCCTTCTTGCGAACCTACTG-3′); RIP1 
sense (5′-CACAGAACCCAGGGACTCAT-3′), RIP1 anti-
sense (5-GACTTCTCTGTGGGCTTTGC-3′); sFRP2 sense 
(5′-ACGAGACCATGAAGGAGGTG-3′), sFRP2 antisense 
(5-GATGCAAAGGTCGTTGTCCT-3′); β-actin sense (5′-CAG-
GTCATCACCATTGGCAATGAGC-3′), β-actin antisense 
(5′-GATGTCCACGTCACACTTCATGA-3′); DNMT1 sense 
(5′-GTGAGGACATGCAGCTTTCA-3′), DNMT1 antisense 
(5′-TGCTGCCTTTGATGTAGTCG-3′); TNFR1-forward 
(5′-TATTG ACTGGTCCCTCACC-3′), TNFR1-reverse (5′-CT-
GCAATTGAAGCACTGGAA-3′). Final PCR products were re-
solved in 1.5% agarose gel and stained with ethidium bromide.
 
Methylation-specific PCR
Genomic DNA was extracted using DNeasy Blood & Tissue 
kits (Qiagen). Methylation status of RIPK3 was determined by 
methylation-specific PCR. Briefly, 2 µg of genomic DNA was 
bisulphite-treated with Zymo DNA Modification Kit (Zymo Re-
search, Orange County, CA, USA). Bisulphite-treated DNA was 
amplified using primers specific for either methylated or unmeth-
ylated DNA. The sequences of the first set of methylated-specific 
(M) primer and unmethylated-specific (U) primer for RIP3 were: 
RIP3 (M), forward 5′-TAATTCGGAAAAAGGGTAATAATTC-3′, 
reverse 5′-ATAAATATCGAAAACTACGATCGAC-3′; RIP3 (U), 
forward 5′-AATTTGGAAAAAGGGTAATAATTTG-3′, reverse 
5′-ATAAATATCAAAAACTACAATCAAC-3′.
The sequences of the second set of methylated-specific (M) 
primer and unmethylated-specific (U) primer for RIP3 were: RIP3 
(M), forward 5′-AGGTTATGGTAAGTTTGGATAACGA-3′, 
reverse 5′-CAACAAACGACAAAAAAACGAC-3′; RIP3 (U), 
forward 5′-AGGTTATGGTAAGTTTGGATAATGA-3′, reverse 
5′-CTTTCAACAAACAACAAAAAAACAA-3′.
Pyrosequencing of bisulfate-converted genomic DNA
Pyrosequencing of RIPK3 Genomic DNA from cells with and 
without 5-AD treatment was performed by Genomictree (Daejeon, 
South Korea) using standard protocols. Briefly, bisulfite-treated 
DNA samples were prepared using EZDNA Methylation-Light-
ning kit (Zymo Research) and then amplified by PCR. The reac-
tion conditions were as follows: 95 °C for 10 min → (95 °C for 
30 s → 56 °C for 30 s → 72 °C for 30 s) 45 cycles → 72 °C for 5 
min. From this reaction, 2 µl of the PCR product was visualized by 
ethidium bromide staining on a 2% agarose gel. The remainder of 
the product underwent pyrosequencing performed on a PyroMark 
ID system (Qiagen) using a PyroGold reagent kit for quantification 
of the methylation level. 
Immunohistochemistry and TUNEL staining
Immunohistochemistry was performed using the UltraVision 
LP Detection System TL-060-HD (Thermo Scientific, Bioanalyt-
ica) according to the manufacturer’s instructions. Thin paraffin 
sections (4.5 µm) were deparaffinized in xylene and rehydrated in 
a graded series of ethanol-aqueous solutions. Antigen retrieval was 
done by heating the slides for 15 min in a microwave oven in 10 
mM citrate buffer (pH 6.0). Endogenous peroxidase activity was 
blocked by incubation in 3% hydrogen peroxide in TBS for 10 
min, then the sections were incubated overnight at 4 °C in 1:300 
dilutions of anti-RIP3 antibody. Chromogen was developed for 
5 min with liquid 3,3′-diaminobenzidine (TL-015-HD, Thermo 
Scientific, Bioanalytica, Greece) and counterstained with Meyer’s 
hematoxylin. Immunohistochemical staining was evaluated based 
on the proportion of stained cells and immunostaining intensity. 
H-score was obtained by multiplying the proportion of stained 
cells (%) and staining intensity graded 0 (negative), 1 (weak), 2 
(moderate), or 3 (strong). H-score ranged from 0 to 300. Staining 
was carried out for tumor and normal tissue for each sample at the 
same time. Staining was interpreted by an experienced patholo-
gist blinded to the clinical data (Ja Seung Koo). TUNEL staining 
was performed following the manufacturer’s protocol (Chemicon, 
Temecula, CA, USA).
Breast cancer subtyping
Breast cancer phenotypes were classified according to the 
immunohistochemistry results for ER, PR, HER-2, and Ki-67 
labeling index and FISH results for HER-2 according to the guide-
lines of Goldhirsch et al. [46]. Classification was as follows: lumi-
nal A type: PR and/or ER positive, HER-2 negative, and Ki-67 LI 
< 14%; luminal B type: (HER-2 negative) PR and/or ER positive, 
HER-2 negative, and Ki-67 LI ≥ 14% and (HER-2 positive) PR 
and/or ER positive and HER-2 overexpressed and/or amplified; 
HER-2 type: PR and ER negative and HER-2 overexpressed and/
or amplified; TNBC type: PR, ER, and HER-2 negative. 
Kaplan-Meier analysis
Kaplan-Meier analysis was done using the Breast Cancer Gene-
Expression Miner v3.0 software designed by Jézéquel et al. [36], 
without respect to nodal status or ER status. Data were pooled 
from studies in references [47-52].
AML methylation and survival analysis
Methylation analysis and survival analysis for AML patients 
was conducted for RIP3 using the methodology and data sets of 
Marcucci et al. [53], with promoter methylation analysis defined 
as 1 kb upstream and 1 kb downstream of TSS.
Tumor xenograft study
Animal care experimental procedures were conducted in ac-
cordance with the approval of the Inha Institutional Animal Care 
and Use Committee (INHA IACUC) at the Medical School of Inha 
University (INHA 131219-256). MDA-MB-231 cells were mixed 
with PBS and Matrigel (200 µl/mouse; suspended in 100 ml of 
PBS mixed with 100 ml of Matrigel), and orthotopically inject-
ed into mammary fat pads of 6-week-old BALB/c nu/nu female 
mice (Central Laboratory, Animal Inc, Seoul, Korea). Mice were 
fed with standard rat chow and tap water ad libitum, and main-
tained under a 12 h dark/light cycle at 21 °C. When the tumors 
had reached a volume of about 80-100 mm3, mice were randomly 
assigned into four groups: untreated, treatment with 5-AD (1 mg/
kg by intraperitoneal injection four times for the first week and 
then 0.1 mg/kg by intraperitoneal injection five times/week) and/
or, doxorubicin (1 mg/kg by intraperitoneal injection three times/
week for the second to third weeks, and then 2 mg/kg to the last 
day). Tumor dimensions were measured twice a week using a dig-
ital caliper and tumor volume was calculated using the formula (V 
= length × width2 × 0.5). Following the experiment, the mice were 
sacrificed and the tumors were excised and weighed. 
Statistical analysis
Statistical analysis was performed using ANOVA and an un-
paired Student’s t-test. A P-value of  0.01 was considered statis-
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tically significant. Statistical calculations were performed using 
SPSS software for Windows Version 12.0 (SPSS, Chicago, IL, 
USA).
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